# Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene

> **NCT03328130** · PHASE1,PHASE2 · TERMINATED · sponsor: **eyeDNA Therapeutics** · enrollment: 19 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** AAV2/5-hPDE6B

## Key facts

- **NCT ID:** NCT03328130
- **Lead sponsor:** eyeDNA Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-06
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** lack of financing
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328130, "Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03328130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*